The University Hospital Centre in Zagreb, Croatia, is the largest hospital in Croatia and the teaching hospital of the University of Zagreb. It serves most of Central and Northern Croatia for specialist and acute medical procedures.

There are 1,800 beds in Klinicki bolnicki centar Zagreb.

During the past decade, Klinicki bolnicki centar Zagreb conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 10 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 7 clinical trials were completed. i.e. 43.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinicki bolnicki centar Zagreb" #1 sponsor was "Klinički Bolnički Centar Zagreb" with 4 trials, followed by "Pfizer" with 4 trials sponsored, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinicki bolnicki centar Zagreb" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "Orient Europharma Co., Ltd." with 1 trials as a collaborator, "Parexel" with 1 trials as a collaborator, "Pharmacyclics LLC." with 1 trials as a collaborator and "Principia Biopharma Australia Pty Ltd." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Klinicki bolnicki centar Zagreb" are "Atrial Fibrillation" (2 trials), "Hemophilia A" (2 trials), "Hemophilia A or B" (2 trials), "Hemophilia B" (2 trials) and "Pulmonary Arterial Hypertension" (2 trials). Many other conditions were trialed in "Klinicki bolnicki centar Zagreb" in a lesser frequency.

Most popular intervention types in "Klinicki bolnicki centar Zagreb" are "Drug" (22 trials), "Biological" (5 trials), "Other" (3 trials), "Procedure" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "PF-06741086" (4 trials), "Rituximab" (2 trials), "Sotatercept" (2 trials) and "Any approved or standard-of-care therapy" (1 trials). Other intervention names were less common.

The vast majority of trials in "Klinicki bolnicki centar Zagreb" are 28 trials for "All" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Klinicki bolnicki centar Zagreb". undefined are not yet recruiting, 11 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Klinicki bolnicki centar Zagreb, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Klinicki bolnicki centar Zagreb, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".